Purple Biotech (PPBT) has released an update.
Purple Biotech has reported significant progress in its clinical programs, with the Phase 2 study of CM24 for pancreatic cancer showing promising biomarker findings that could enhance patient outcomes. The company also highlighted its financial performance for the third quarter of 2024, with reduced losses and a cash runway extending into late 2025, positioning it for potential partnerships. New data from their CAPTN-3 platform was also presented, showcasing its versatility and potential in cancer treatment.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
